Long Covid & ME/CFS: New Hope for BC 007 (Rovunaptabin) Treatment?
Long COVID Drug BC007 Gets a Second Chance with New Biotech Firm APTA Therapeutics After a disappointing Phase 2 trial led to the insolvency of Berlin Cures, the future of BC007 – a potential treatment targeting the root causes of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID – looked bleak. Now, a new biotech … Read more